Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,758,850
  • Shares Outstanding, K 98,176
  • Annual Sales, $ 248,070 K
  • Annual Income, $ -63,560 K
  • 60-Month Beta 2.40
  • Price/Sales 31.38
  • Price/Cash Flow N/A
  • Price/Book 48.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.05
  • Number of Estimates 5
  • High Estimate 0.00
  • Low Estimate -0.08
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.71 +12.68%
on 09/10/19
98.70 -17.00%
on 08/21/19
-11.79 (-12.59%)
since 08/16/19
3-Month
56.02 +46.24%
on 06/26/19
98.70 -17.00%
on 08/21/19
+23.89 (+41.15%)
since 06/17/19
52-Week
26.02 +214.85%
on 11/20/18
98.70 -17.00%
on 08/21/19
+35.58 (+76.75%)
since 09/17/18

Most Recent Stories

More News
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting

--Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first presentation of in vitro data combining treatment with Tumor...

NVCR : 81.81 (+3.52%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 46.26 (+0.59%)
AYX : 117.36 (+3.05%)
ROKU : 150.52 (+0.66%)
IWP : 144.48 (+0.79%)
NVCR : 81.81 (+3.52%)
IJK : 227.74 (-0.13%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 46.26 (+0.59%)
FCN : 110.26 (+2.01%)
IWP : 144.48 (+0.79%)
NVCR : 81.81 (+3.52%)
PODD : 145.07 (+1.38%)
IJK : 227.74 (-0.13%)
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune(R) in China

Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called...

NVCR : 81.81 (+3.52%)
ZLAB : 34.91 (+1.93%)
Novocure to Participate in Three Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences.

NVCR : 81.81 (+3.52%)
NovoCure Limited (NVCR) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).

NVCR : 81.81 (+3.52%)
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 85.71% and 6.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 81.81 (+3.52%)
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update

--The NovoTTF-100L(TM) System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure's first FDA-approved torso indication

NVCR : 81.81 (+3.52%)
Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference

Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology (EMB) Conference, July 23 through...

NVCR : 81.81 (+3.52%)
CMS Establishes 2019 Monthly Fee Schedule Amount for Optune(R)

Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount...

NVCR : 81.81 (+3.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 80.64
1st Resistance Point 79.83
Last Price 81.81
1st Support Level 77.88
2nd Support Level 76.74

See More

52-Week High 98.70
Last Price 81.81
Fibonacci 61.8% 70.94
Fibonacci 50% 62.36
Fibonacci 38.2% 53.78
52-Week Low 26.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar